Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a clinical study ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, Se ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Incyte’s second quarter was marked by broad-based strength across its commercial portfolio, reflected in a significant ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Stamoulis joins Mallinckrodt from Incyte, a leading biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. In addition ...

Mallinckrodt plc today announced the appointment of Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Ms. Stamoulis, currently the EVP and Chief Financial ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

WILMINGTON, Del. (AP) — WILMINGTON, Del. (AP) — Incyte Corp. (INCY) on Tuesday reported second-quarter net income of $405 million. The Wilmington, Delaware-based company said it had profit of $2.